<DOC>
	<DOC>NCT01322321</DOC>
	<brief_summary>This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.</brief_summary>
	<brief_title>ACZ885 in Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>diagnosis of type 1 diabetes within 3 months of visit 1 and on a stable insulin regimen presence of at least one diabetesrelated autoantibody qualifying Cpeptide value in a mixed meal test at visit 1 willing to not have vaccination with a live vaccine for 18 months, from 3 months before visit 1 until 3 months after the last dose of study drug body weight of at least 30 kg women of childbearing potential unless a highly effective method of birth control is used (such as combined oral contraceptives, intrauterine devices, etc) immunodeficiency active infections or febrile illness within 3 days before visit 1 major dental work within 8 days before visit 1 positive test for tuberculosis at visit 1 use of medications other than insulin for the treatment of diabetes Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>ACZ885</keyword>
	<keyword>diabetes</keyword>
	<keyword>type 1</keyword>
	<keyword>C-peptide</keyword>
</DOC>